ArisGlobal

Life Sciences · Artificial Intelligence · Enterprise Software

Acquisition

Dassault Systèmes to buy ArisGlobal for up to $2B in AI life sciences deal

It pairs real-world patient safety data with clinical R&D software, aiming to build life sciences' first end-to-end AI compliance platform.

• Dassault Systèmes agreed to acquire ArisGlobal from private equity firm Nordic Capital for about $1.8 billion in cash plus up to $200 million tied to AI revenue milestones, a deal worth up to $2 billion.
• ArisGlobal's LifeSphere platform is an AI-native compliance system for regulatory, safety and quality workflows, serving over 200 customers including half of the top 50 global biopharma firms, and processes more than 12 million patient safety reports a year.
• Founded in 1989 and based in Waltham, Massachusetts, ArisGlobal employs more than 1,300 people and is projected to generate $175 million in revenue in 2026.
• Nordic Capital first invested in ArisGlobal in 2019 at a reported $700 million valuation, added a further stake in 2021, and exits fully through this sale.
• The life sciences compliance software market ArisGlobal operates in is projected to grow to $7.5 billion by 2030 as AI captures a larger share of enterprise spending.
• The deal is Dassault's largest since its $5.8 billion acquisition of clinical trials software maker Medidata in 2019, and comes as Dassault's own Life Sciences segment revenue fell 4% in the latest quarter.
• Fusing ArisGlobal's patient-level safety and regulatory data with Dassault's R&D and manufacturing software aims to give pharma firms a unified AI system spanning discovery to real-world outcomes, a bet that compliance-grade AI becomes a core life sciences platform layer.